Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Investigational Drugs Right
  3. Orforglipron-Obesity Right
  4. What orforglipron clinical trials are being conducted in people with obesity or overweight?
Search Orforglipron - Obesity (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Orforglipron-Obesity

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.

What orforglipron clinical trials are being conducted in people with obesity or overweight?

The ATTAIN and ADVANCE-ATTAIN clinical trial programs evaluate investigational doses of orforglipron for the treatment of obesity or overweight in adult and pediatric participants with or without comorbidities, respectively.

US_cFAQ_OFG020B_ATTAIN_CLINICAL_TRIALS_CWM
US_cFAQ_OFG020B_ATTAIN_CLINICAL_TRIALS_CWMen-US

Orforglipron Clinical Trial Program for the Treatment of Obesity or Overweight

Orforglipron is a novel, once-daily, oral, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) being developed for the treatment of obesity or overweight and the treatment of type 2 diabetes (T2D).1

ATTAIN Clinical Trials in Adult Participants

The ATTAIN clinical trial program assesses the efficacy and safety of investigational doses of orforglipron as a treatment for obesity or overweight in adult participants (Overview of the ATTAIN Phase 3 Clinical Trial Program of Orforglipron for the Treatment of Obesity or Overweight in Adult Participants).

Overview of the ATTAIN Phase 3 Clinical Trial Program of Orforglipron for the Treatment of Obesity or Overweight in Adult Participants

Trial and Target Population

Key Inclusion Criteria

Orforglipron Groups

Comparator

Primary Endpoint(s)

Primary Timepoint

Global Trials

ATTAIN-12
in People With Obesity or Overweight

NCT05869903

  • BMI ≥30 kg/m2, or
  • BMI ≥27 kg/m2 with ≥1 weight-related comorbidity without T2Da

Administered PO

PBO

Percent CFB in BW

72 weeks

ATTAIN-23
in People With Obesity or Overweight and T2D

NCT05872620

  • BMI ≥27 kg/m2
  • T2D

Administered PO

PBO

Percent CFB in BW

72 weeks

ATTAIN-OSA4
in People With OSA and Obesity or Overweight

NCT06649045

  • BMI ≥27 kg/m2
  • AHI ≥15 on PSG as part of the trial at screening (visit 1)b

Administered PO

PBO

CFB in AHI

52 weeks

ATTAIN-HYPERTENSTION5-7,c
in People With Hypertension and Obesity or Overweight

NCT06948422

  • SBP ≥140 mm Hg and/or DBP ≥90 mm Hg at screening or week 0 (visit 1 or visit 3)d
  • Untreated for HTN, or on stable antihypertensive medications ≥30 days prior to visit 1
  • BMI ≥25 kg/m²

Administered PO

PBO

CFB in office SBP

36 weeks 

Regional Trials

ATTAIN-J8
in Japanese People With Obesity

NCT05931380

  • BMI ≥27 kg/m2 and <35 kg/m2 and at least 2 obesity-related health problemse
  • BMI ≥35 kg/m2 and at least 1 obesity-related health probleme

Administered PO

PBO

Percent CFB in BW

72 weeks

ATTAIN-MAINTAIN9
in People With Obesity or Overweight

NCT06584916

  • Have completed the SURMOUNT-5 study on study treatment10f

Administered PO

PBO

Percent maintenance of BW reduction achieved in SURMOUNT-5

52 weeks

Abbreviations: AHI = apnea-hypopnea index; BMI = body mass index; BW = body weight; CFB = change from baseline; DBP = diastolic blood pressure; HTN = hypertension; OSA = obstructive sleep apnea; PAP = positive airway pressure; PBO = placebo; PO = orally; PSG = polysomnography; SBP = systolic blood pressure; T2D = type 2 diabetes. 

aComorbidities included hypertension, dyslipidemia, OSA, and cardiovascular disease.

bATTAIN-OSA is a master protocol designed to support 2 independent studies, GZ01 and GZ02. The key inclusion criteria for GZ01 include participants who are unable or unwilling to use PAP therapy and have not used PAP for at least 4 weeks prior to screening. For GZ02, the key inclusion criteria include participants who have been on PAP therapy for at least 3 consecutive months prior to the study start and plan to continue PAP therapy during the study.

cATTAIN-HYPERTENSION is a master protocol designed to support 2 independent studies, GZL1 and GZL2.

dIf DBP criteria alone is met, SBP must be ≥130 mm Hg.

eObesity-related health problems can be treated or untreated and should include either hypertension, dyslipidemia, or T2D.

fKey inclusion criteria for the SURMOUNT-5 study were a BMI ≥30 kg/m² or ≥27 kg/m² and previously diagnosed with at least 1 of the following weight-related comorbidities, hypertension, dyslipidemia, OSA, or cardiovascular disease, and have a history of at least 1 unsuccessful dietary effort to lose BW.

ADVANCE-ATTAIN Clinical Trials in Pediatric Patients

ADVANCE is a phase 3 master protocol (PWMP) evaluating the safety and efficacy of obesity therapies for the treatment of obesity or overweight in pediatric participants.11

This PWMP establishes entry criteria for participants across the

  • master protocol, and
  • intervention-specific appendices.11

See Overview of the ADVANCE-ATTAIN Phase 3 Clinical Trial Program of Orforglipron for the Treatment of Obesity or Overweight in Pediatric Participants for more information on trials in the ADVANCE-ATTAIN orforglipron clinical trial program. 

Overview of the ADVANCE-ATTAIN Phase 3 Clinical Trial Program of Orforglipron for the Treatment of Obesity or Overweight in Pediatric Participants

Trial and Target Population

Key Inclusion Criteria 

Orforglipron
Groups 

Comparator

Primary Endpoint

Primary Timepoint

Global

ADVANCE-ATTAIN-ADOLESCENTS12
in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

NCT06672939

  • Age 12-17 years 
  • History of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification programa
  • BMI ≥95th percentileb
  • BMI ≥85th percentile and ≤95th percentile with at least 1 weight-related comorbidityb,c

Administered PO

PBO

Percent CFB in BMI

72 weeks

Abbreviations: BMI = body mass index; CDC = Centers for Disease Control and Prevention; CFB = change from baseline; NCHS = National Center for Health Statistics; MASH = metabolic dysfunction-associated steatohepatitis; MASLD = metabolic dysfunction-associated steatotic liver disease; PBO = placebo; PO = orally; T2D = type 2 diabetes.

a Must have undergone diet and exercise counseling for at least 3 months prior to screening.

bBased on age- and gender-specific growth chart determined by CDC-NCHS (2022).

cComorbidities include hypertension, T2D, prediabetes, dyslipidemia, obstructive sleep apnea, MASH, or MASLD.

Clinical Trials Comparing Orforglipron and GLP-1 RAs

Eli Lilly and Company does not have any ongoing clinical trials comparing the efficacy and safety of orforglipron with injectable GLP-1 RAs or tirzepatide. 

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Wharton S, Blevins T, Connery L, et al; GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. https://doi.org/10.1056/NEJMoa2302392

2A study of orforglipron (LY3502970) in adult participants with obesity or overweight with weight-related comorbidities (ATTAIN-1). ClinicalTrials.gov identifier: NCT05869903. Updated October 8, 2024. Accessed November 27, 2024. https://clinicaltrials.gov/study/NCT05869903

3A study of orforglipron in adult participants with obesity or overweight and type 2 diabetes (ATTAIN-2). ClinicalTrials.gov identifier: NCT05872620. Updated October 16, 2024. Accessed November 27, 2024. https://clinicaltrials.gov/study/NCT05872620

4A master protocol for orforglipron in participants with obstructive sleep apnea and obesity or overweight (ATTAIN-OSA). ClinicalTrials.gov identifier: NCT06649045. Updated November 22, 2024. Accessed November 27, 2024. https://clinicaltrials.gov/study/NCT06649045

5A master protocol for orforglipron (LY3502970) in participants with hypertension and obesity or overweight: (ATTAIN-Hypertension screening). ClinicalTrials.gov identified NCT: NCT06948422. Updated April 29, 2025. Accessed May 2, 2025. https://clinicaltrials.gov/study/NCT06948422

6A master protocol study of orforglipron (LY3502970) in participants with hypertension and obesity or overweight (ATTAIN-Hypertension) GZL1. ClinicalTrials.gov identifier: NCT06952530. Updated April 29, 2025. Accessed May 12, 2025. https://clinicaltrials.gov/study/NCT06948435?term=GZL1&rank=1

7A master protocol study of orforglipron (LY3502970) in participants with hypertension and obesity or overweight (ATTAIN-Hypertension) GZL2. ClinicalTrials.gov identifier: NCT06952530. Updated May 1, 2025. Accessed May 12, 2025. https://clinicaltrials.gov/study/NCT06952530?term=GZL2&rank=1

8A study of once-daily oral orforglipron (LY3502970) in Japanese adult participants with obesity disease (ATTAIN-J). ClinicalTrials.gov identifier: NCT05931380. Updated August 27, 2024. Accessed November 27, 2024. https://clinicaltrials.gov/study/NCT05931380

9A study of orforglipron for the maintenance of body weight reduction in participants who have obesity or overweight with weight-related comorbidities (ATTAIN-MAINTAIN). ClinicalTrials.gov identifier: NCT06584916. Updated October 23, 2024. Accessed November 27, 2024. https://clinicaltrials.gov/study/NCT06584916

10A study of tirzepatide (LY3298176) in participants with obesity or overweight with weight related comorbidities (SURMOUNT-5). ClinicalTrials.gov identifier: NCT05822830. Updated August 27, 2024. Accessed December 6, 2024. https://clinicaltrials.gov/study/NCT05822830

11A platform trial for pediatric participants with obesity or overweight (LY900040) (ADVANCE). ClinicalTrials.gov identifier: NCT06672549. Updated April 18, 2025. Accessed April 18, 2025. https://clinicaltrials.gov/study/NCT06672549

12A study of orforglipron (LY3502970) in adolescent participants with obesity, or overweight with related comorbidities. ClinicalTrials.gov identifier: NCT06672939. Updated April 18, 2025. Accessed April 18, 2025. https://clinicaltrials.gov/study/NCT06672939

Date of Last Review: April 18, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly